Press Release:
Gx Inbeneo^® autoinjector wins the Red Dot Award

The 2024 Red Dot Design Concept award for the Gx Inbeneo^® highlights its innovative pre-pressurized design and patient-focused features, which allow for the safe and straightforward self-administration of very highly viscous liquid drugs.  
In addition, the platform concept allows for easy customization, enabling pharmaceutical companies to swiftly bring combination products to market.  
 
The award recognizes the Gx Inbeneo^® autoinjector platform as an innovative solution that meets the needs of pharmaceutical customers and patients. It has been developed by Gerresheimer in cooperation with Midas Pharma.  

About Midas pharma 
Midas Pharma is a pharmaceutical company based in Ingelheim, Germany, that offers products, services, and expertise along the entire pharmaceutical value chain from Starting Materials and Active Pharmaceutical Ingredients to market ready Finished Products and Devices. Since over three decades the family-owned company has successfully contributed to the Pharma sector and has step by step expanded its competencies. With more than 300 employees and 12 locations in all major pharmaceutical markets worldwide Midas Pharma has excellent local know-how, local contacts, and well-established networks in different pharmaceutical sectors (biological products, small molecules and medical devices). Thanks to many years of experience and extensive expertise, Midas Pharma has a proven track record of successfully supporting its customers in coordinating even complex pharmaceutical projects and creating significant added value. 
 

About Gerresheimer   
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, dropper bottles, other bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. With around 12,000 employees, the company generated revenues of around €2bn in 2023. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).